Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Scandinavian Journal of Pain

Official Journal of the Scandinavian Association for the Study of Pain

Editor-in-Chief: Breivik, Harald


CiteScore 2017: 0.84

SCImago Journal Rank (SJR) 2017: 0.401
Source Normalized Impact per Paper (SNIP) 2017: 0.452

Online
ISSN
1877-8879
See all formats and pricing
More options …
Volume 5, Issue 2

Issues

Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series

Heinrich Wernze / Thomas Herdegen
  • Corresponding author
  • Institute of Clinical and Experimental Pharmacology, University of Kiel, Arnold-Heller-Straße 3, Haus 30, 24105 Kiel, Germany
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-04-01 | DOI: https://doi.org/10.1016/j.sjpain.2013.12.003

Abstract

Objective

No single drug is broadly efficacious in the long-term treatment of fibromyalgia syndrome (FMS). Spironolactone is known to ameliorate mood and tension headache or migraine in women with premenstrual syndrome or clinical signs of hyperandrogenism. In a case series of women with treatment resistant FMS spironolactone was therefore added to their medication, and they were observed for at least 12 months.

Methods

31 women with treatment-resistant FMS received spironolactone as add-on medication to various pain modulating drugs. 15 women responded to spironolactone and baseline data were compared with assessments over 12–14 months on treatment with spironolactone (ALDACTONE®) in dose range 100–200 mg/day. The efficacy was evaluated by the fibromyalgia impact questionnaire (FIQ) total score and 8 FIQ subtests, a German mood inventory (BSKE-EWL), and further assessments of changes in relevant psychological and physical complaints. 16 women had no effect and stopped the treatment early.

Results

The subsequent data refer to the 15 responders. The FIQ total score (maximal score = 80) decreased from 56.6 ± 10.0 at baseline to 17.1 ± 11.9 (mean ± SD) 12–14 months later, and pain intensity on an 11 point numeric rating scale (NRS) decreased from 8.8 ± 1.6 to 2.6 ± 1.9 (mean ± SD). Similar changes in FIQ subscores were found for fatigue, morning tiredness, stiffness, anxiety, and depression. Emotional functioning consistently improved: positive mood from 20.0 ± 5.4 to 37.7 ± 5.4 (maximal score = 48), and negative mood from 35.4 ± 5.3 to 10.0 ± 4.4 (maximal score = 60) (each mean ± SD) as well as other mental and physical dysfunctions including non-restorative sleep. All these changes at 4–6 weeks remained on this level for 11–13 months. The drug was well-tolerated and safe, no serious adverse effects were observed. Regular monitoring of serum potassium did not reveal hyperkalemia. All 15 women were able to reduce or discontinue concomitant drugs.

Conclusion

Fifteen of 31 women with otherwise treatment-resistant FMS experienced a number of prolonged beneficial effects from spironolactone on their complex pain-condition.

Implications and discussion

We hypothesise that spironolactone affects several central and peripheral neurotransmitter systems such as γ-aminobutyric acid (GABA) activity and dopaminergic transmission. The high rate of non-responsive patients underlines that FMS may represent several subgroups. Pain relief and improvement of associated FHS-symptoms and positive effects on additional diseases or dysfunctions give reasons for marked and sustained improvement in the quality of life.

Well-controlled, double-blind, and randomised trials are necessary to confirm our potentially very important observations.

Keywords: Aldosterone; Analgesics; Fibromyalgia syndrome; Mineralocorticoid-receptor; Neurosteroids

References

  • [1]

    Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007;146:726–34.PubMedCrossrefGoogle Scholar

  • [2]

    Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain 2009;10:777–91.PubMedCrossrefGoogle Scholar

  • [3]

    Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992;19:846–50.PubMedGoogle Scholar

  • [4]

    Hauser W, Bernardy K, Arnold B, Offenbacher M, Schiltenwolf M. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum 2009;61:216–24.CrossrefPubMedGoogle Scholar

  • [5]

    Clauw DJ. Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry 2008;69:25–9.PubMedGoogle Scholar

  • [6]

    Staud R. Treatment of fibromyalgia and its symptoms. Expert Opin Pharmacother 2007;8:1629–42.CrossrefPubMedGoogle Scholar

  • [7]

    Aslaksen K, Falk V. Spironolactone in the treatment of premenstrual tension: a double-blind study of spironolactone versus bendroflumethiazide and placebo. Curr Ther Res Clin Exp 1991;49:120–9.Google Scholar

  • [8]

    Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007;36:339–56.PubMedCrossrefGoogle Scholar

  • [9]

    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, Masi AT, Masi AT, Masi AT, Masi AT, Masi AT. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72.PubMedCrossrefGoogle Scholar

  • [10]

    Offenbaecher M, Waltz M, Schoeps P. Validation of a German version of the fibromyalgia impact questionnaire (FIQ-G). J Rheumatol 2000;27:1984–8.PubMedGoogle Scholar

  • [11]

    Hueppe M, Uhlig T, Heinze J, Vogelsang H, Schmucher P. Management and methodological approaches for the assessment of emotional states in anesthesiology. Anaesthesiol Intensivmed Notfallmed Schmerzther 2000;35:3–11.Google Scholar

  • [12]

    Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989;29:342–7.PubMedCrossrefGoogle Scholar

  • [13]

    Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin S, Perera P, Russell IJ, Simon L, Spaeth M, Williams D, Williams D. Fibromyalgia syndrome. J Rheumatol 2007;34:1415–25.PubMedGoogle Scholar

  • [14]

    Hudson JI, Pope Jr HG. Fibromyalgia and psychopathology: is fibromyalgia a form of “affective spectrum disorder”? J Rheumatol Suppl 1989;19:15–22.PubMedGoogle Scholar

  • [15]

    Crane MG, Harris JJ. Effect of spironolactone in hypertensive patients. Am J Med Sci 1970;260:311–30.PubMedCrossrefGoogle Scholar

  • [16]

    Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000;52:587–94.CrossrefPubMedGoogle Scholar

  • [17]

    Hudson JI, Goldenberg DL, Pope Jr HG, Keck Jr PE, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992;92:363–7.PubMedCrossrefGoogle Scholar

  • [18]

    Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012;26:297–307.PubMedCrossrefGoogle Scholar

  • [19]

    Carta M, Ruggiero V, Sancassiani F, Cutrano F, Manca A, Peri M, Fais A, Cacace E. The use of antidepressants in the long-term treatment should not improve the impact of fibromyalgia on quality of life. Clin Pract Epidemiol Ment Health 2013;9:120–4.CrossrefPubMedGoogle Scholar

  • [20]

    Staud R, Vierck CJ, Robinson ME, Price DD. Overall fibromyalgia pain is predicted by ratings of local pain and pain-related negative affect – possible role of peripheral tissues. Rheumatology (Oxford) 2006;45:1409–15.PubMedCrossrefGoogle Scholar

  • [21]

    Zautra AJ, Fasman R, Reich JW, Harakas P, Johnson LM, Olmsted ME, Davis MC. Fibromyalgia: evidence for deficits in positive affect regulation. Psychosom Med 2005;67:147–55.CrossrefPubMedGoogle Scholar

  • [22]

    van Eijk-Hustings Y, Kroese M, Boonen A, Bessems-Beks M, Landewe R. Predictors for health improvement in patients with fibromyalgia: a 2-year follow-up study. J Clin Rheumatol 2013. Aug 24. [Epub ahead of print].Google Scholar

  • [23]

    Guichard JL, Clark 3rd D, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013;9:321–31.PubMedGoogle Scholar

  • [24]

    Sutanto W, de Kloet ER. Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects. Med Res Rev 1991;11:617–39.PubMedCrossrefGoogle Scholar

  • [25]

    Smythe JW, Murphy D, Timothy C, Costall B. Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats. Pharmacol Biochem Behav 1997;56:507–13.CrossrefPubMedGoogle Scholar

  • [26]

    Smythe JW, Murphy D, Timothy C, Gul GH, Costall B. Cognitive dysfunctions induced by scopolamine are reduced by systemic or intrahippocampal mineralocorticoid receptor blockade. Pharmacol Biochem Behav 1997;56:613–21.CrossrefPubMedGoogle Scholar

  • [27]

    Sutanto W, Handelmann G, Bree F, Kloet ER. Multifaceted interaction of corticosteroids with the intracellular receptors and with membrane GABA receptor complex in the rat brain. J Neuroendocrinol 1989;1:243–7.CrossrefPubMedGoogle Scholar

  • [28]

    Abshagen U, Sporl S, Schoneshofer M, L’Age M, Oelkers W. Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism. Klin Wochenschr 1978;56:341–9.CrossrefPubMedGoogle Scholar

  • [29]

    Sakamoto H, Ichikawa S, Sakamaki T, Nakamura T, Ono Z, Takayama Y, Murata K. Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism. Am J Hypertens 1990;3:533–7.PubMedCrossrefGoogle Scholar

  • [30]

    Rupprecht R, Holsboer F. Neuropsychopharmacological properties of neuroactive steroids. Steroids 1999;64:83–91.PubMedCrossrefGoogle Scholar

  • [31]

    Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog Neurobiol 1992;38:379–95.CrossrefPubMedGoogle Scholar

  • [32]

    Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999;22:410–6.CrossrefPubMedGoogle Scholar

  • [33]

    Morrow AL, Devaud LL, Purdy RH, Paul SM. Neuroactive steroid modulators of the stress response. Ann N Y Acad Sci 1995;771:257–72.CrossrefPubMedGoogle Scholar

  • [34]

    Pathirathna S, Todorovic SM, Covey DF, Jevtovic-Todorovic V. 5alpha-reduced neuroactive steroids alleviate thermal and mechanical hyperalgesia in rats with neuropathic pain. Pain 2005;117:326–39.PubMedCrossrefGoogle Scholar

  • [35]

    Frye CA, Paris JJ, Walf AA, Rusconi JC. Effects and mechanisms of 3alpha, 5alpha-THP on emotion, motivation, and reward functions involving pregnane xenobiotic receptor. Front Neurosci 2011;5:136.PubMedGoogle Scholar

  • [36]

    Pisu MG, Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Sci 2004;74:3181–97.CrossrefPubMedGoogle Scholar

  • [37]

    Uzunova V, Sampson L, Uzunov DP. Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology (Berl) 2006;186:351–61.PubMedCrossrefGoogle Scholar

  • [38]

    Knabl J, Witschi R, Hosl K, Reinold H, Zeilhofer UB, Ahmadi S, Brockhaus J, Sergejeva M, Hess A, Brune K, Fritschy JM, Rudolph U, Mohler H, Zeilhofer HU. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008;451:330–4.CrossrefPubMedGoogle Scholar

  • [39]

    Jones BE. The sleep-wake-cycle: basic mechanisms. J Rheumatol Suppl 1989;19:49–51.PubMedGoogle Scholar

  • [40]

    Moldofsky H, Scarisbrick P, England R, Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975;37:341–51.PubMedCrossrefGoogle Scholar

  • [41]

    Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27.PubMedGoogle Scholar

  • [42]

    Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550–6.CrossrefPubMedGoogle Scholar

  • [43]

    Wood PB, Patterson 2nd JC, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007;8:51–8.PubMedCrossrefGoogle Scholar

  • [44]

    Moore H, Rose HJ, Grace AA. Chronic cold stress reduces the spontaneous activity of ventral tegmental dopamine neurons. Neuropsychopharmacology 2001;24:410–9.PubMedCrossrefGoogle Scholar

  • [45]

    Pani L, Porcella A, Gessa GL. The role of stress in the pathophysiology of the dopaminergic system. Mol Psychiatry 2000;5:14–21.PubMedCrossrefGoogle Scholar

  • [46]

    Wood PB. Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Med Hypotheses 2004;62:420–4.CrossrefPubMedGoogle Scholar

  • [47]

    Biswas B, Carlsson A. The effect of intracerebroventricularly administered GABA on brain monoamine metabolism. Naunyn Schmiedebergs Arch Pharmacol 1977;299:41–6.CrossrefPubMedGoogle Scholar

  • [48]

    Kalivas PW, Duffy P, Eberhardt H. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. J Pharmacol Exp Ther 1990;253:858–66.PubMedGoogle Scholar

  • [49]

    Maciejak P, Krzascik P, Czlonkowska AI, Szyndler J, Bidzinski A, Walkowiak J, Kostowski W, Plaznik A. Antagonism of picrotoxin-induced changes in dopamine and serotonin metabolism by allopregnanolone and midazolam. Pharmacol Biochem Behav 2002;72:987–91.CrossrefPubMedGoogle Scholar

  • [50]

    Rouge-Pont F, Mayo W, Marinelli M, Gingras M, Le Moal M, Piazza PV. The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens. Eur J Neurosci 2002;16:169–73.CrossrefPubMedGoogle Scholar

  • [51]

    Dong F, He X. Pro-nociceptive role of the activation of mineralocorticoid receptor in the pathogenesis of painful diabetic neuropathy. Med Hypotheses 2013;81:436–8.CrossrefPubMedGoogle Scholar

  • [52]

    Dong F, Xie W, Strong JA, Zhang JM. Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. Anesthesiology 2012;117:1102–12.CrossrefPubMedGoogle Scholar

  • [53]

    Lilius TO, Jokinen V, Neuvonen MS, Vaananen AJ, Niemi M, Rauhala PV, Kalso EA. The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception. Eur J Pain 2013, http://dx.doi.org/10.1002/j.1532-2149.2013.00371 [Epub ahead of print].PubMed

  • [54]

    Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013;154:2310–6.PubMedCrossrefGoogle Scholar

  • [55]

    Uceyler N, Sommer C. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013;154:2569.PubMedCrossrefGoogle Scholar

  • [56]

    Doggrell SA, Brown L. The spironolactone renaissance. Expert Opin Investig Drugs 2001;10:943–54.CrossrefPubMedGoogle Scholar

  • [57]

    Hendler NH. Spironolactone prophylaxis in manic-depressive disease. J Nerv Ment Dis 1978;166:517–20.PubMedCrossrefGoogle Scholar

  • [58]

    Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995;74:803–8.CrossrefPubMedGoogle Scholar

  • [59]

    Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20:469–74.PubMedGoogle Scholar

  • [60]

    Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 1998;83:3339–45.PubMedGoogle Scholar

  • [61]

    Corbould A. Effects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women. Horm Metab Res 2007;39:915–8.CrossrefPubMedGoogle Scholar

  • [62]

    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17.CrossrefPubMedGoogle Scholar

  • [63]

    Bendtzen K, Hansen PR, Rieneck K. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003;134:151–8.PubMedCrossrefGoogle Scholar

  • [64]

    Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010;24:532–7.PubMedCrossrefGoogle Scholar

  • [65]

    Schmidt-Wilcke T, Clauw DJ. Pharmacotherapy in fibromyalgia (FM) – implications for the underlying pathophysiology. Pharmacol Ther 2010;127:283–94.CrossrefPubMedGoogle Scholar

About the article

Tel.: +49 431 597 3502


Received: 2013-10-25

Revised: 2013-12-02

Accepted: 2013-12-30

Published Online: 2014-04-01

Published in Print: 2014-04-01


Conflict of interest: The authors receive no funds and declare no conflict of interests.

Contribution of authorsThe clinical part of this observational case series that started in 2001, and the intellectual design of the manuscript were exclusively performed by H. W.T. H. contributed to the writing and submission of the manuscript.


Citation Information: Scandinavian Journal of Pain, Volume 5, Issue 2, Pages 63–71, ISSN (Online) 1877-8879, ISSN (Print) 1877-8860, DOI: https://doi.org/10.1016/j.sjpain.2013.12.003.

Export Citation

© 2014 Scandinavian Association for the Study of Pain.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Bahar Gürlek Demirci, Emre Tutal, Mehtap Erkmen, Elçin Erdoğan, and Siren Sezer
The European Research Journal, 2018

Comments (0)

Please log in or register to comment.
Log in